Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATAI 
ATAI Life Sciences BV (ATAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ATAI (3-star) is a STRONG-BUY. BUY since 104 days. Simulated Profits (223.91%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.38
1 Year Target Price $11.38
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.04% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.40B USD | Price to earnings Ratio - | 1Y Target Price 11.38 |
Price to earnings Ratio - | 1Y Target Price 11.38 | ||
Volume (30-day avg) 7 | Beta 1.59 | 52 Weeks Range 1.04 - 6.30 | Updated Date 10/15/2025 |
52 Weeks Range 1.04 - 6.30 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3515.02% |
Management Effectiveness
Return on Assets (TTM) -29.51% | Return on Equity (TTM) -76.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1114899116 | Price to Sales(TTM) 607.48 |
Enterprise Value 1114899116 | Price to Sales(TTM) 607.48 | ||
Enterprise Value to Revenue 482.85 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 233779400 | Shares Floating 160106445 |
Shares Outstanding 233779400 | Shares Floating 160106445 | ||
Percent Insiders 7.71 | Percent Institutions 41.28 |
Upturn AI SWOT
ATAI Life Sciences BV
Company Overview
History and Background
ATAI Life Sciences BV was founded in 2018 as a biopharmaceutical company focused on developing psychedelic and non-psychedelic compounds for various mental health disorders. It has grown through acquisitions and partnerships, aiming to create a pipeline of innovative therapies.
Core Business Areas
- Drug Development: Developing novel therapies for mental health disorders using psychedelic and non-psychedelic compounds.
- Platform Development: Building technology platforms to support drug development and patient care.
- Investment: Investing in and partnering with other companies in the mental health space.
Leadership and Structure
The company is led by a team with experience in biotechnology, pharmaceuticals, and venture capital. Florian Brand is the CEO. It operates through a decentralized structure with various platform companies.
Top Products and Market Share
Key Offerings
- PCN-101 (R-ketamine): PCN-101 is an R-ketamine formulation in Phase 2 trials for treatment-resistant depression (TRD). Market share data is not yet available as the product is still in development. Competitors include Johnson & Johnson (SPRAVATO), and other companies developing ketamine alternatives.
- RL-007: RL-007 is a Phase 2 ready compound being explored for cognitive impairment associated with schizophrenia (CIAS). Market share data is not yet available as the product is still in development. Competitors include companies developing cognitive enhancers such as Cerevel Therapeutics (CERE).
- VLS-01: VLS-01 is a study being explored for social anxiety disorder. Market share data is not yet available as the product is still in development. Competitors include companies developing anxiety treatments such as Axsome Therapeutics (AXSM).
Market Dynamics
Industry Overview
The mental health therapeutics market is experiencing significant growth, driven by increased awareness, rising prevalence of mental disorders, and growing acceptance of alternative therapies. There is substantial investment and innovation in psychedelic medicine.
Positioning
ATAI Life Sciences BV is positioned as a leading company in the psychedelic medicine space, with a diverse pipeline of potential therapies. Its competitive advantage lies in its portfolio approach, decentralized structure, and access to capital.
Total Addressable Market (TAM)
The global mental health market is estimated to be worth hundreds of billions of dollars. ATAI Life Sciences BV is positioned to address unmet needs within specific mental health conditions, with a multi-pronged strategy to capture a portion of the TAM.
Upturn SWOT Analysis
Strengths
- Diverse pipeline of therapeutic candidates
- Strong financial backing and access to capital
- Experienced leadership team
- Decentralized structure promoting innovation
- Early mover advantage in the psychedelic medicine space
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Regulatory uncertainty surrounding psychedelic compounds
- Lack of marketed products
- Complexity of managing multiple platform companies
Opportunities
- Growing acceptance of psychedelic therapies
- Increasing prevalence of mental health disorders
- Potential for breakthrough therapies
- Partnerships with established pharmaceutical companies
- Expansion into new indications and geographies
Threats
- Competition from other companies in the psychedelic space
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
- Negative public perception of psychedelic drugs
Competitors and Market Share
Key Competitors
- GHRS
- MNMD
- CMPS
Competitive Landscape
ATAI Life Sciences BV faces competition from other companies developing psychedelic therapies, as well as established pharmaceutical companies with existing mental health treatments. ATAI's advantage lies in its diverse pipeline and focus on novel mechanisms of action.
Major Acquisitions
Perception Neuroscience
- Year: 2020
- Acquisition Price (USD millions): 20.7
- Strategic Rationale: Acquired Perception Neuroscience to gain access to PCN-101 (R-ketamine), a promising treatment for depression.
Growth Trajectory and Initiatives
Historical Growth: Historically the company grew through acquisitions and securing investment. Currently, they are growing by progressing clinical trials.
Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates vary widely due to the uncertainty surrounding the psychedelic medicine space.
Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, expanding partnerships, and exploring new therapeutic indications.
Summary
ATAI Life Sciences BV is a company pioneering mental health treatment using psychedelic compounds and novel drugs. While possessing a broad pipeline and sufficient funding, it faces substantial risks common to early stage biotech companies. These risks are in the form of regulatory uncertainty, capital intensive clinical trials, and reliance on eventual regulatory approval for revenue generation. The market outlook for this treatment of depression is huge if ATAI passes these risks and threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ATAI Life Sciences BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-18 | Co-Founder, CEO & Executive Director Dr. Srinivas G. Rao M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://atai.com |
Full time employees 54 | Website https://atai.com | ||
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Amstelveen, The Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.